There are currently 67 active clinical trials seeking participants for Neoplasms research studies. The states with the highest number of trials for Autism participants are California, Texas, Florida and New York.
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
All
Ages:
Between 1 year and 39 years
Trial Updated:
04/16/2024
Locations: Childrens Hospital of Alabama, Birmingham, Alabama +67 locations
Conditions: Neoplasms, Child, Adolescent
Register for Updates
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
NCT03194893
Recruiting
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Gender:
All
Ages:
All
Trial Updated:
04/15/2024
Locations: Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California +34 locations
Conditions: Neoplasms
Register for Updates
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
NCT02333604
Recruiting
The Cancer Experience Registry®: An Online Survey Research Study to Understand the Experiences of Those Impacted By a Cancer Diagnosis. The Registry is a web-based platform to distribute cross-sectional and longitudinal surveys. Study surveys are designed based on input from advisor experts, including patients and caregivers, and focus on the social, emotional, physical, financial and decision-making experiences of those who have been diagnosed with cancer and their caregivers. Findings contribu... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Cancer Support Community Research & Training Institute, Washington, District of Columbia
Conditions: Neoplasms, Cancer, Caregiver
Register for Updates
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel
NCT04449549
Recruiting
Background: People with rare cancers often have limited treatment options. The biology of rare cancers is not well understood. Researchers want to find better treatments for these cancers. They want to test 2 drugs that, taken separately, have helped people with non-rare cancers. They want to see if these drugs together can make rare cancers shrink or stop growing. Objective: To learn if nilotinib and paclitaxel will benefit people with rare cancers. Eligibility: People age 18 and older who... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
04/11/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms
Register for Updates
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
NCT06077877
Recruiting
The primary purpose of this study is to determine the maximum tolerated dose of GSK4524101 monotherapy (MTD) and GSK4524101 in combination with niraparib (MTDc). The study consists of two parts - Part 1 (Dose Escalation) and Part 2 (Dose Expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: GSK Investigational Site, San Francisco, California +9 locations
Conditions: Neoplasms
Register for Updates
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
NCT05209295
Recruiting
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: University of Iowa, Iowa City, Iowa +21 locations
Conditions: Hepatic Insufficiency, Neoplasms
Register for Updates
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
NCT04711109
Recruiting
This phase III trial compares denosumab to placebo for the prevention of breast cancer in women with a BRCA1 germline mutation. A germline mutation is an inherited gene change which, in the BRCA1 gene, is associated with an increased risk of breast and other cancers. Denosumab is a monoclonal antibody that is used to treat bone loss in order to reduce the risk of bone fractures in healthy people, and to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research h... Read More
Gender:
Female
Ages:
Between 25 years and 55 years
Trial Updated:
04/08/2024
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California +41 locations
Conditions: BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Register for Updates
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
NCT06285097
Recruiting
This study aims to evaluate the safety, and early signals of anti-tumor activity of PF-07820435 when administered alone (Part 1A) or in combination with sasanlimab (Part 1B; Part 2) in patients with selected advanced or metastatic solid tumors. Part 1 will be dose-finding and Part 2 of the study will further evaluate PF-07820435 at the recommended dose for combination expansion in patients with selected advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Corewell Health (reference non-engagement letter), Grand Rapids, Michigan +5 locations
Conditions: Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Register for Updates
A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors)
NCT04958239
Recruiting
This study is open to adults with advanced cancer (solid tumors). People for whom previous treatment was not successful can take part in this study. The purpose of this study is to find the highest dose of a medicine called BI 765179 that people with solid tumors can tolerate when taken alone or together with a medicine called ezabenlimab. Each participant is put into one of two groups. Participants get BI 765179 alone or in combination with ezabenlimab as infusion into a vein every 3 weeks.... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: University of Arizona, Tucson, Arizona +7 locations
Conditions: Neoplasms
Register for Updates
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
NCT03366116
Recruiting
Background: Blood, tissue, and tumor cells contain genes. Genes are made up of DNA. DNA is the instruction book for each cell. In some people with cancer, the genes that might have slowed the growth of their tumor were turned off. Researchers want to see if a new drug can turn the genes back on and slow the tumor growth. The drug is called Aza-TdC. Objective: To test the safety of Aza-TdC, and to find out the dose of this drug that can be safely given to humans. Eligibility: People ages 18... Read More
Gender:
All
Ages:
Between 18 years and 120 years
Trial Updated:
03/28/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neoplasms, Solid Tumors
Register for Updates
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02632448
Recruiting
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +15 locations
Conditions: Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Colon Cancer, Rectal Cancer, Neoplasms, Endometrial Cancer, Soft Tissue Sarcoma, Triple Negative Breast Cancer, Pancreas Cancer, Pancreatic Cancer
Register for Updates
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
NCT04008797
Recruiting
The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: University of California San Diego (UCSD) - Moores Cancer Center(All), La Jolla, California +47 locations
Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms
Register for Updates